Action ANL ADLAI NORTYE LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Adlai Nortye Ltd.

Actions

ANL

US00704R1095

Marché Fermé - Nasdaq
Autres places de cotation
 22:30:00 06/06/2024 		Varia. 5j. Varia. 1 janv.
4,29 USD -17,53% Graphique intraday de Adlai Nortye Ltd. -44,29% -52,28%
24/05 Adlai Nortye Ltd. annonce qu'elle présentera des données encourageantes sur l'association de l'AN0025 et de la chimioradiothérapie définitive (dCRT) à l'ASCO 2024 CI
22/05 Adlai Nortye annonce que le premier patient a été traité dans le cadre de l'essai clinique randomisé de phase II sur Palupiprant (An0025) pour le traitement du cancer du rectum localement avancé par radiothérapie. CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
Adlai Nortye Ltd. Announces to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy At ASCO 2024
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
Adlai Nortye Announces First Patient Dosed in Randomized Phase Ii Clinical Trial of Palupiprant for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
ADRs Advance, Eco Wave Power Global AB Climbs 213.4%
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
Adlai Nortye Announces Appointment of Archie Tse as the Head of Research & Development
Certain Class B Ordinary Shares of Adlai Nortye Ltd. are subject to a Lock-Up Agreement Ending on 28-MAR-2024.
Certain Class A Ordinary Shares of Adlai Nortye Ltd. are subject to a Lock-Up Agreement Ending on 28-MAR-2024.
Adlai Nortye : Term of use
Adlai Nortye Says it has Completed Patient Enrollment in Phase 3 Trial of Buparlisib
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award
Adlai Nortye : in collaboration with Nucleai, to Present "Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN" at ESMO 2023
Adlai Nortye Ltd. Announces Closing of Initial Public Offering
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ANL
  4. Actualités Adlai Nortye Ltd.
  5. Autres langues